{
    "name": "tezepelumab",
    "comment": "Rx",
    "other_names": [
        "Tezspire",
        "tezepelumab-ekko"
    ],
    "classes": [
        "Monoclonal Antibodies",
        "Anti-asthmatics"
    ],
    "source": "https://reference.medscape.com/drug/tezspire-tezepelumab-4000235",
    "pregnancy": {
        "common": [
            "Data are not available regarding use in pregnant females to evaluate for any drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes",
            "Placental transfer of monoclonal antibodies is greater during third trimester; therefore, potential effects on fetus are likely to be greater during that time"
        ],
        "specific": [
            {
                "type": "Animal studies",
                "description": [
                    "In an enhanced prenatal and postnatal development study conducted in cynomolgus monkeys, placental transport of tezepelumab observed",
                    "There was no evidence of fetal harm following IV administration throughout pregnancy at doses that produced maternal exposures up to 168 times the exposure at the maximum recommended human dose (MRHD) of 210 mg administered SC"
                ]
            },
            {
                "type": "Clinical considerations",
                "description": [
                    "Females with poorly or moderately controlled asthma have increased risk of preeclampsia in the mother and prematurity, low birth weight, and small for gestational age, in the neonate",
                    "Closely monitor asthma control in pregnant females and adjust treatment to maintain optimal control"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "Data are not available regarding the presence of tezepelumab in human milk, effects on breastfed infants, or effects on milk production",
            "IgG is present in human milk in small amounts; tezepelumab was present in the milk of cynomolgus monkeys postpartum following dosing during pregnancy",
            "Consider the developmental and health benefits of breastfeeding along with the mother's clinical need for tezepelumab and any potential adverse effects on the breastfed infant or from the underlying maternal condition"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity to tezepelumab or its excipients"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Hypersensitivity reactions (eg, rash and allergic conjunctivitis) can occur after administration; typically occur within hours of administration, but some instances have a delayed onset (ie, days); in event of a hypersensitivity reaction, consider benefits and risks to determine whether to continue or discontinue treatment ",
                "Do not use to treat acute asthma symptoms, acute exacerbations, acute bronchospasm, or status asthmaticus; instruct patient to seek medical attention if asthma remains uncontrolled or worsens after treatment initiation",
                "Do not discontinue systemic or inhaled corticosteroids abruptly upon initiating therapy; reduce corticosteroid dose gradually, if appropriate, under direct supervision of a physician",
                "Treat preexisting helminth infection before initiating; if patients become infected while taking tezepelumab and do not respond to antihelminth treatment, discontinue tezepelumab until infection resolves",
                "Concomitant use with live, attenuated vaccines has not been evaluated; avoid administering live vaccines while taking tezepelumab"
            ],
            "specific": []
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Pharyngitis",
            "percent": "4"
        },
        {
            "name": "Arthralgia",
            "percent": "4"
        },
        {
            "name": "Back pain",
            "percent": "4"
        },
        {
            "name": "Injection",
            "percent": "3.3"
        },
        {
            "name": "site reactions",
            "percent": null
        }
    ]
}